Recent Advances in Endometrial Cancer [version 1; referees: 2 approved]

Endometrial cancer is the most common gynecologic malignancy in the United States, with yearly rates continuing to increase. Most women present with early stage disease; however, advanced disease carries a grave prognosis. As a result, novel therapies are currently under investigation for the treatm...

Full description

Bibliographic Details
Main Authors: Arthur-Quan Tran, Paola Gehrig
Format: Article
Language:English
Published: F1000 Research Ltd 2017-01-01
Series:F1000Research
Subjects:
Online Access:https://f1000research.com/articles/6-81/v1
id doaj-0df450ce446344cda7134aae28ce2640
record_format Article
spelling doaj-0df450ce446344cda7134aae28ce26402020-11-25T03:02:46ZengF1000 Research LtdF1000Research2046-14022017-01-01610.12688/f1000research.10020.110796Recent Advances in Endometrial Cancer [version 1; referees: 2 approved]Arthur-Quan Tran0Paola Gehrig1Gynecologic Oncology, University of North Carolina at Chapel Hill, NC, USAGynecologic Oncology, University of North Carolina at Chapel Hill, NC, USAEndometrial cancer is the most common gynecologic malignancy in the United States, with yearly rates continuing to increase. Most women present with early stage disease; however, advanced disease carries a grave prognosis. As a result, novel therapies are currently under investigation for the treatment of endometrial cancer. These advances include a better understanding of the genetic basis surrounding the development of endometrial cancer, novel surgical therapies, and new molecular targets for the treatment of this disease. This review explores the literature regarding these advancements in endometrial cancer.https://f1000research.com/articles/6-81/v1Cancer TherapeuticsGynecological CancersImmunopharmacology & Hematologic PharmacologyMedical GeneticsPharmacogenomics
collection DOAJ
language English
format Article
sources DOAJ
author Arthur-Quan Tran
Paola Gehrig
spellingShingle Arthur-Quan Tran
Paola Gehrig
Recent Advances in Endometrial Cancer [version 1; referees: 2 approved]
F1000Research
Cancer Therapeutics
Gynecological Cancers
Immunopharmacology & Hematologic Pharmacology
Medical Genetics
Pharmacogenomics
author_facet Arthur-Quan Tran
Paola Gehrig
author_sort Arthur-Quan Tran
title Recent Advances in Endometrial Cancer [version 1; referees: 2 approved]
title_short Recent Advances in Endometrial Cancer [version 1; referees: 2 approved]
title_full Recent Advances in Endometrial Cancer [version 1; referees: 2 approved]
title_fullStr Recent Advances in Endometrial Cancer [version 1; referees: 2 approved]
title_full_unstemmed Recent Advances in Endometrial Cancer [version 1; referees: 2 approved]
title_sort recent advances in endometrial cancer [version 1; referees: 2 approved]
publisher F1000 Research Ltd
series F1000Research
issn 2046-1402
publishDate 2017-01-01
description Endometrial cancer is the most common gynecologic malignancy in the United States, with yearly rates continuing to increase. Most women present with early stage disease; however, advanced disease carries a grave prognosis. As a result, novel therapies are currently under investigation for the treatment of endometrial cancer. These advances include a better understanding of the genetic basis surrounding the development of endometrial cancer, novel surgical therapies, and new molecular targets for the treatment of this disease. This review explores the literature regarding these advancements in endometrial cancer.
topic Cancer Therapeutics
Gynecological Cancers
Immunopharmacology & Hematologic Pharmacology
Medical Genetics
Pharmacogenomics
url https://f1000research.com/articles/6-81/v1
work_keys_str_mv AT arthurquantran recentadvancesinendometrialcancerversion1referees2approved
AT paolagehrig recentadvancesinendometrialcancerversion1referees2approved
_version_ 1724688499606552576